GLP-1 Drugs Linked to Fewer Psychiatric Hospitalizations in People With Schizophrenia and Type 2 Diabetes
A Lancet Psychiatry cohort of 70,257 schizophrenia patients shows GLP-1 agonists reduce acute psychiatric care. Trial design hasn't caught...
GLP-1 Receptor Agonists
Orforglipron’s MACE Data Just Raised the Evidentiary Bar for Every Oral GLP-1 Program Behind It
Orforglipron's ACHIEVE-4 trial showed MACE-4 in 4.2% vs. 5.0% for insulin glargine, now every oral small-molecule GLP-1 program faces...
GLP-1 Agonists Reduce AUD Hospitalizations — But Stopping Them Is a Clinical Decision We’re Not Ready For
Lancet Psychiatry data show GLP-1 agonists cut AUD hospitalizations, with protection lasting 182 days post-discontinuation. Here's what that means...
GLP-1s Are Cutting My AUD Patients’ Hospitalizations. Trial Designers Need to Know Why.
A Lancet Psychiatry study links GLP-1 receptor agonists to fewer AUD and SUD hospitalizations—but the post-discontinuation signal demands a...
GLP-1 Agonists Are Quietly Reducing Addiction Hospitalizations, But Only While Patients Take Them
A Lancet Psychiatry study shows GLP-1 agonists cut AUD and SUD hospitalizations, but the protection fades after stopping —...
Reading the SYNCHRONIZE-MASLD Phase 3 Trial Publication Closely
The SYNCHRONIZE-MASLD Phase 3 trial in Nature Medicine shows survodutide cutting liver fat by 64.3% vs placebo — here's...
Aleniglipron’s Phase 2b Data Redraws the Oral GLP-1 Efficacy Map — And Raises Hard Questions for Phase 3 Design
Structure Therapeutics' aleniglipron hit 14.7% weight loss in Phase 2b, matching injectable benchmarks. Here's what the trial design signals...
Semaglutide Just Changed the Math on Alcohol Use Disorder — and Every Addiction Trial Sponsor Should Be Paying Attention
A Lancet RCT shows once-weekly semaglutide cut heavy drinking days in obese AUD patients — targeting a condition where...
Semaglutide’s Alcohol Data Is Stronger Than Anyone Expected — and the FDA Has No Playbook for It
A landmark Lancet RCT shows once-weekly semaglutide cuts alcohol use in obesity patients with AUD. The FDA's regulatory pathway...
Semaglutide Just Passed Its Hardest Test Yet — And the FDA Has No Roadmap for What Comes Next
A landmark Lancet RCT shows once-weekly semaglutide cut heavy drinking days in 108 AUD-plus-obesity patients. The FDA approval path...